Behavioral and endocrine response to cholecystokinin tetrapeptide in patients with posttraumatic stress disorder

Biological Psychiatry

Volumn 47, Issue 2, 2000, Pages 107-111

  Kellner, Michael ^a   Wiedemann, Klaus ^a   Yassouridis, Alexander ^a   Levengood, Robert ^b   Guo, Ling Song ^b   Holsboer, Florian ^a   Yehuda, Rachel ^b  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cholecystokinin tetrapeptide; Cortisol; Dissociation; Flashbacks; Panic; Posttraumatic stress disorder

Indexed keywords

CORTICOTROPIN; HYDROCORTISONE; PLACEBO; TETRAGASTRIN;

ADULT; ANXIETY; ARTICLE; BEHAVIOR; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOTROPIN BLOOD LEVEL; DOUBLE BLIND PROCEDURE; FEMALE; HORMONE RELEASE; HUMAN; HYDROCORTISONE BLOOD LEVEL; MALE; NEGATIVE FEEDBACK; PANIC; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL;

ADRENOCORTICOTROPIC HORMONE; ADULT; CORTICOTROPIN-RELEASING HORMONE; DOUBLE-BLIND METHOD; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; HYDROCORTISONE; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; PANIC DISORDER; STRESS DISORDERS, POST-TRAUMATIC; TETRAGASTRIN;

EID: 0033985485     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(99)00118-3     Document Type: Article

References (32)

1. Aluoja A., Shlik J., Vasar V., Kingisepp P.H., Jagomagi K., Vasar E., Bradwejn J. Emotional and cognitive factors connected with response to cholecystokinin tetrapeptide in healthy volunteers. Psychiatr Res. 66:1997;59-67.
2. Bernstein E.M., Putnam F.W. Development, reliability, and validity of a dissociation scale. J Nerv Ment Dis. 174:1986;727-735.
3. Biró E., Sarnyai Z., Penke B., Szabo G., Telegdy G. Role of endogenous corticotropin-releasing factor in mediation of neuroendocrine and behavioral responses to cholecystokinin octapeptide sulfate in rats. Neuroendocrinology. 57:1993;340-345.
4. Bradwejn J., Koszycki D., Bourin M. Dose ranging study of the effects of cholecystokinin in healthy volunteers. J Psychiatry Neurosci. 16:1991;91-95.
5. Bremner J.D., Licino J., Darnell A., Krystal J.H., Owens M.J., Southwick S.M., et al. Elevated CSF corticotropin-releasing factor concentrations in posttraumatic stress disorder. Am J Psychiatry. 154:1997;624-629.
6. Coupland N.J., Lillywhite A., Bell C.E., Potokar J.P., Nutt D.J. A pilot controlled study of the effects of flumazenil in posttraumatic stress disorder. Biol Psychiatry. 41:1997;988-990.
7. First MB, Spitzer RL, Gibbon M (1995): Structured clinical interview for DSM-IV axis I disorders - patient edition (SCID-I/P, version 2.0). New York: Biometrics Research Department, NYSPI.
8. Flint A., Koszycki D., Vaccarino F., Carieux A., Boulenger P., Bradwejn J. The effect of aging on cholecystokinin-induce panic. Am J Psychiatry. 155:1998;283-285.
9. Giolas M.H., Sanders B. Pain and suffering as a function of dissociation levels and instructional set. Dissociation. 5:1992;205-209.
10. Harro J., Vasar E., Bradwejn J. CCK in animal and human research on anxiety. TiPS. 14:1993;244-249.
11. Jensen C.F., Keller T.W., Peskind E.R., McFall M.E., Veith R.C., Martin D., et al. Behavioral and neuroendocrine responses to sodium lactate infusions in subjects with posttraumatic stress disorder. Am J Psychiatry. 154:1997;266-268.
12. Jensen C.F., Keller T.W., Peskind E.R., McFall M.E., Veith R.C., Martin D., et al. Behavioral and plasma cortisol responses to sodium lactate infusion in posttraumatic stress disorder. Ann NY Acad Sci. 821:1997;444-448.
13. Josselyn S.A., Frankland P.W., Petrisano S., Bush D.E., Yeomans J.S., Vaccarino J.F. The CCK-B antagonist, L-365,260, attenuates fear-potentiated startle. Peptides. 16:1995;1313-1315.
14. Kellner M., Knaudt K., Jahn H., Holsboer F., Wiedemann K. Atrial natriuretic hormone in lactate-induced panic attacks mode of release and endocrine and pathophysiological consequences . J Psychiatr Res. 32:1998;37-48.
15. Kellner M., Levengood R., Yehuda R., Wiedemann K. Provocation of a posttraumatic flashback by cholecystokinin tetrapeptide? Am J Psychiatry. 155:1998;1299.
16. Kellner M., Yassouridis A., Jahn H., Wiedemann K. Influence of clonidine on psychopathological, endocrine and respiratory effects of cholecystokinin tetrapeptide in patients with panic disorder. Psychopharmacology. 133:1997;55-61.
17. Koszycki D., Cox B.J., Bradwejn J. Anxiety sensitivity and response to cholecystokinin tetrapeptide in healthy volunteers. Am J Psychiatry. 150:1983;1881-1883.
18. Koszycki D., Zacharko R.M., Le Mélledo J.-M., Bradwejn J. Behavioral, cardiovascular, and neuroendocrine profiles following CCK-4 challenge in healthy volunteers a comparison of panickers and nonpanickers . Depr Anxiety. 8:1998;1-7.
19. Koszycki D., Zacharko R.M., Le Mélledo J.-M., Young S.N., Bradwejn J. Effect of acute tryptophan depletion on behavioral, cardiovascular and hormonal sensitivity to cholecystokinin-tetrapeptide challenge in healthy volunteers. Biol Psychiatry. 40:1996;648-655.
20. Mellman T.A., Davis G.C. Combat-related flashbacks in posttraumatic stress disorder phenomenology and similarity to panic attacks . J Clin Psychiatry. 6:1985;79-382.
21. Michelson J., June K., Vives A., Testa S., Marchione N. The role of trauma and dissociation in cognitive-behavioral psychotherapy outcome and maintenance for panic disorder with agoraphobia. Behav Res Ther. 36:1998;1011-1050.
22. Rainey J.M., Aleem A., Ortiz A., Yeragani V., Pohl R., Berchou R. A laboratory procedure for the induction of flashbacks. Am J Psychiatry. 144:1987;1317-1319.
23. Randall P.K., Bremner J.D., Krystal J.H., Nagy L.M., Heninger G.R., Nicolaou A.L. Effects of the benzodiazepine antagonist flumazenil in PTSD. Biol Psychiatry. 38:1995;319-324.
24. Reiss S., Peterson R.A., Gursky D.M., McNally R.J. Anxiety sensitivity, anxiety frequency and the prediction of fearfulness. Behav Res Ther. 24:1986;1-8.
25. Shlik J., Aluoja A., Vasar V., Vasar E., Podar T., Bradwejn J. Effects of citalopram treatment on behavioral, cardiovascular, and neuroendocrine response to cholecystokinin tetrapeptide challenge in panic disorder patients. J Psychiatr Neurosci. 22:1997;332-340.
26. Smith M.A., Davidson J., Ritchie J.C., Kudler H., Lipper S., Chappell P., et al. The corticotropin-releasing hormone test in patients with posttraumatic stress disorder. Biol Psychiatry. 26:1989;349-355.
27. Southwick S.M., Krystal J.H., Bremner J.D., Morgan C.A., Nicolaou A.L., Nagy L.M., et al. Noradrenergic and serotoninergic function in posttraumatic stress disorder. Arch Gen Psychiatry. 54:1997;749-758.
28. Southwick S.M., Krystal J.H., Morgan C.A., Johnson D., Nagy L.M., Nicolaou A., et al. Abnormal noradrenergic function in posttraumatic stress disorder. Arch Gen Psychiatry. 50:1993;266-274.
29. Ströhle A., Kellner M., Yassouridis A., Holsboer F., Wiedemann K. Effect of flumazenil in lactate-sensitive patients with panic disorder. Am J Psychiatry. 55:1998;610-612.
30. Yehuda R., Boissoneau D., Mason J.W., Giller E.L. Dose-response changes in plasma cortisol and lymphocyte glucocorticoid receptors following dexamethasone administration in combat veterans with and without posttraumatic stress disorder. Arch Gen Psychiatry. 52:1995;583-593.
31. Yehuda R., Levengood R.A., Schmeidler J., Wilson S., Guo L.S., Gerber D. Increased activation following metyrapone administration in post-traumatic stress disorder. Psychoneuroendocrinology. 21:1996;1-16.
32. Yehuda R., Southwick S.M., Krystal J.H., Bremner D., Charney D.S., Mason J.W. Enhanced suppression of cortisol following dexamethasone administration in posttraumatic stress disorder. Am J Psychiatry. 140:1993;83-86.